Skip to content

On this page

Praxbind

idarucizumab

351(a) Standalone BLA

Overview

Source: Purple Book

Proprietary name

Praxbind

Proper name

idarucizumab

Licence type

351(a)

BLA number

761025

Applicant

Boehringer Ingelheim Pharmaceuticals, Inc.

Center

CDER

Presentations

1

First licensure

—

Presentations

Source: Purple Book

Every strength and presentation recorded in the Purple Book for this product.
Strength	Dosage form	Route	Presentation	Status	Licensed
2.5G/50ML	Injection	Intravenous	Single-Dose Vial	Rx	October 16, 2015

Exclusivity

Source: Purple Book

Kind	Expires
Orphan exclusivity	October 16, 2022

Sources for this page

Purple Book	FDA	Licence type, presentations, reference product, exclusivity